Founded Year

1891

Stage

IPO | IPO

Date of IPO

1/1/1919

Market Cap

211.34B

Stock Price

84.61

Revenue

$0000 

About Merck

Merck focuses on developing medicines and vaccines. The company provides products for preventing and treating various diseases in humans and animals, including oncology, infectious diseases, cardio-metabolic disorders, immunology, neuroscience, and ophthalmology. Merck also utilizes data science and artificial intelligence in their therapeutic approaches. Merck was formerly known as Schering Plough. It was founded in 1891 and is based in Rahway, New Jersey.

Headquarters Location

126 East Lincoln Avenue

Rahway, New Jersey, 07065,

United States

908-740-4000

Loading...

Loading...

Research containing Merck

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Merck in 3 CB Insights research briefs, most recently on Jul 3, 2025.

Merck Patents

Merck has filed 5635 patents.

The 3 most popular patent topics include:

  • transcription factors
  • clusters of differentiation
  • monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/23/2020

4/8/2025

Multiple sclerosis, Autoimmune diseases, Pharmacokinetics, Dosage forms, Antineoplastic drugs

Grant

Application Date

10/23/2020

Grant Date

4/8/2025

Title

Related Topics

Multiple sclerosis, Autoimmune diseases, Pharmacokinetics, Dosage forms, Antineoplastic drugs

Status

Grant

Latest Merck News

Adenosine Global Market Report 2025| Business Growth, Development Factors, Current and Future Trends till 2029

Sep 10, 2025

The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, September 10, 2025 / EINPresswire.com / -- "Get 30% Off All Global Market Reports With Code ONLINE30 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors How Much Is The Adenosine Market Worth? The size of the adenosine market has seen swift growth in recent years. The market which was valued at $0.98 billion in 2024 is expected to surge to $1.09 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 11.4%. The historical growth in this market can be linked to several factors including an increase in cardiovascular diseases, a growing number of cardiac arrhythmias cases, an aging population susceptible to heart-related conditions, enhanced research on the function of adenosine in cancer treatment and immunotherapy, along with an increasing demand for adenosine-focused therapies. In the coming years, the size of the adenosine market is predicted to experience a swift expansion. It's projected to reach a market value of $1.65 billion by 2029 with a compound annual growth rate (CAGR) of 11.0%. Factors contributing to this growth during the projected period include an increase in cardiovascular diseases, developing uses in cancer immunotherapy, a surge in investments in pharmaceutical research and development, government backing for drug innovation, and the advancement of healthcare infrastructure in emerging markets. Key trends expected during this period consist of advancements in drug delivery technologies, novel approaches to adenosine receptor targeting, the creation of controlled-release formulations, research and progression in neuromodulation therapies, and the incorporation of adenosine in combination therapies. Download a free sample of the adenosine market report: https://www.thebusinessresearchcompany.com/sample.aspx?id=27197&type=smp What Are The Factors Driving The Adenosine Market? The upward trend of cardiovascular diseases is anticipated to stimulate the expansion of the adenosine market. These diseases, referring to a collection of disorders that impact the heart and blood vessels, include ailments like coronary heart disease, heart failure, stroke, and hypertension. The rise in these cases can largely be attributed to unhealthy diets which include excessive intake of saturated fats, trans fats, added sugars, and sodium. These diet elements contribute to high blood pressure, obesity and increased cholesterol levels. The role of adenosine in this scenario is critical as it aids in managing cardiovascular diseases by regulating heart rhythm and enhancing heart blood flow. Asides providing fast relief in some arrhythmias, it also supports diagnostic processes, thus improving cardiovascular treatment and patient safety. To emphasize this point, data from January 2024, from the American Heart Association, a nonprofit organization based in the U.S., revealed that the age-adjusted death rate as a result of cardiovascular disease rose to 233.3 per 100,000 in 2022, an increase of 4.0% from 224.4 per 100,000 in 2021. Therefore, the rising prevalence of cardiovascular diseases is a key driver for growth in the adenosine market. Who Are The Major Players In The Adenosine Market? Major players in the Adenosine Global Market Report 2025 include: • Pfizer Inc. • F. Hoffmann-La Roche Ltd • Merck & Co. Inc. • Teva Pharmaceutical Industries Ltd. • Astellas Pharma Inc. • Ajinomoto Co. Inc. • Cadila Pharmaceuticals Ltd. • Emcure Pharmaceuticals Ltd. • Gland Pharma Limited • Wockhardt Ltd. What Are The Key Trends And Market Opportunities In The Adenosine Sector? Leading entities in the adenosine market are shifting their focus towards the creation of novel drug delivery mechanisms, such as single-use glass vials, to enhance the effectiveness and safety of adenosine application during urgent situations. Single-dose glass vials are small, sealed glass vessels that contain a single dose of a particular medication for single-use only. For example, Meitheal Pharmaceuticals Inc., a US-based biopharmaceutical organization, in June 2025, introduced an adenosine injection. This injection is packaged in single-dose glass vials, specifically in 60 mg/20 mL and 90 mg/30 mL quantities. This progress facilitates ongoing peripheral intravenous infusion and is designed to mitigate errors in manual dosing, facilitate quick standardized administration, and make cardiac emergency hospital workflows more efficient. This development serves as a significant step in the progress of injectable treatments, leading to improved patient results and operational effectiveness in critical healthcare settings. Which Segment Accounted For The Largest Adenosine Market Share? The adenosine market covered in this report is segmented 1) By Type: Natural Adenosine, Synthetic Adenosine 2) By Delivery Method: Intravenous (IV) Administration, Oral Administration, Topical Administration 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel 4) By Application: Cardiovascular Diseases, Neurological Disorders, Cancer Treatment, Immunotherapy 5) By End-user: Hospitals, Clinics, Research Laboratories, Pharmaceutical Companies Subsegments: 1) By Natural Adenosine: Plant Derived, Animal Derived, Microbial Fermented 2) By Synthetic Adenosine: Chemically Synthesized, Enzymatically Synthesized, Biotechnologically Produced View the full adenosine market report: https://www.thebusinessresearchcompany.com/report/adenosine-global-market-report What Are The Regional Trends In The Adenosine Market? In the Adenosine Global Market Report 2025, North America took the lead as the biggest market in 2024. The region predicted to experience the most growth is Asia-Pacific. In the report, the markets analyzed encompass Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Browse Through More Reports Similar to the Global Adenosine Market 2025, By The Business Research Company Teleprotection Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/teleprotection-global-market-report Tele Intensive Care Unit Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/tele-intensive-care-unit-global-market-report Construction And Heavy Equipment Telematics Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/construction-and-heavy-equipment-telematics-global-market-report Speak With Our Expert: Saumya Sahay Americas +1 310-496-7795 Asia +44 7882 955267 & +91 8897263534 Europe +44 7882 955267 Email: saumyas@tbrc.info The Business Research Company - www.thebusinessresearchcompany.com Follow Us On: • LinkedIn: https://in.linkedin.com/company/the-business-research-company Oliver Guirdham The Business Research Company info@tbrc.info Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Merck Frequently Asked Questions (FAQ)

  • When was Merck founded?

    Merck was founded in 1891.

  • Where is Merck's headquarters?

    Merck's headquarters is located at 126 East Lincoln Avenue, Rahway.

  • What is Merck's latest funding round?

    Merck's latest funding round is IPO.

  • Who are Merck's competitors?

    Competitors of Merck include Kenvue, AbbVie, AstraZeneca, Daiichi Sankyo, Acadia and 7 more.

Loading...

Compare Merck to Competitors

S
Sumitomo Pharma

Sumitomo Pharma is a biopharmaceutical company focused on developing therapeutic and scientific breakthroughs. The company's main offerings include the development of novel cancer therapeutics and a robust pipeline of treatments aimed at addressing unmet clinical needs in oncology. Sumitomo Pharma was formerly known as Sumitomo Dainippon Pharma. It was founded in 1897 and is based in Osaka, Japan.

P
Pfizer

Pfizer is a biopharmaceutical company involved in the discovery, development, and manufacturing of medications and vaccines aimed at improving health outcomes. The company serves the healthcare sector with its medical solutions. It is based in Jakarta, Indonesia.

LifeArc Logo
LifeArc

LifeArc operates as a self-financing medical research charity. The organization specializes in drug discovery, diagnostics development, antibody humanization, and intellectual property management, aiming to lab-based scientific discoveries into diagnostics, treatments, and cures. LifeArc collaborates with various sectors including the pharmaceutical industry, biotechnology sector, and academic institutions to develop and commercialize medical research. LifeArc was formerly known as MRC Technology. It was founded in 2000 and is based in London, United Kingdom.

B
Boehringer Ingelheim

Boehringer Ingelheim is involved in healthcare within the pharmaceutical and animal health sectors. The company conducts research and development of products for humans and animals. Boehringer Ingelheim serves the healthcare industry with an emphasis on pharmaceutical products. It was founded in 1885 and is based in Ingelheim am Rhein, Germany.

Johnson & Johnson Innovative Medicine Logo
Johnson & Johnson Innovative Medicine

Johnson & Johnson Innovative Medicine focuses on the development and manufacturing of pharmaceutical products. The company offers a range of medicines aimed at treating complex diseases in areas such as cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, oncology, and pulmonary arterial hypertension. It collaborates globally, engaging in research and development to bring transformative therapies to patients. It was formerly known as Janssen Pharmaceuticals. It was founded in 1953 and is based in Raritan, New Jersey. In October 2010, Janssen Pharmaceuticals was acquired by Johnson & Johnson at a valuation of $2.4B.

Cerba HealthCare Logo
Cerba HealthCare

Cerba HealthCare provides medical diagnostics within the healthcare sector. It offers diagnostic services including proximity biology, specialty biology, clinical trial biology, anatomical and cytological pathology, medical imaging, and preventive biology. These services are used for the diagnosis and management of diseases. It was founded in 1967 and is based in Issy-les-Moulineaux, France.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.